- Home
- ARQT vs HCI Comparison
ARQT vs HCI Comparison
Compare ARQT & HCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- HCI
- Stock Information
- Founded
- ARQT 2016
- HCI 2006
- Country
- ARQT United States
- HCI United States
- Employees
- ARQT N/A
- HCI N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- HCI Property-Casualty Insurers
- Sector
- ARQT Health Care
- HCI Finance
- Exchange
- ARQT Nasdaq
- HCI Nasdaq
- Market Cap
- ARQT 1.7B
- HCI 1.7B
- IPO Year
- ARQT 2020
- HCI N/A
- Fundamental
- Price
- ARQT $14.29
- HCI $138.80
- Analyst Decision
- ARQT Strong Buy
- HCI Strong Buy
- Analyst Count
- ARQT 7
- HCI 4
- Target Price
- ARQT $18.67
- HCI $181.25
- AVG Volume (30 Days)
- ARQT 1.5M
- HCI 131.1K
- Earning Date
- ARQT 08-06-2025
- HCI 08-07-2025
- Dividend Yield
- ARQT N/A
- HCI 1.15%
- EPS Growth
- ARQT N/A
- HCI 4.05
- EPS
- ARQT N/A
- HCI 10.46
- Revenue
- ARQT $212,819,000.00
- HCI $759,870,000.00
- Revenue This Year
- ARQT $61.83
- HCI $19.25
- Revenue Next Year
- ARQT $36.55
- HCI $4.08
- P/E Ratio
- ARQT N/A
- HCI $13.27
- Revenue Growth
- ARQT 100.03
- HCI 20.95
- 52 Week Low
- ARQT $7.86
- HCI $87.01
- 52 Week High
- ARQT $17.75
- HCI $176.40
- Technical
- Relative Strength Index (RSI)
- ARQT 46.02
- HCI 36.37
- Support Level
- ARQT $14.44
- HCI $137.02
- Resistance Level
- ARQT $15.38
- HCI $141.48
- Average True Range (ATR)
- ARQT 0.66
- HCI 3.02
- MACD
- ARQT -0.09
- HCI 0.30
- Stochastic Oscillator
- ARQT 10.19
- HCI 18.26
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.